SEARCH

SEARCH BY CITATION

References

  • 1
    Dorn CR, Taylor DO and Hibbard HH. Epizootiologic characteristics of canine and feline leukemia and lymphoma. American Journal of Veterinary Research 1967; 28: 9931001.
  • 2
    Teske E. Prognostic factors for malignant lymphoma in the dog: an update. Veterinary Quarterly 1994; 16(Suppl. 1): 29S31S
  • 3
    Vail DM, Kravis LD, Kisseberth WC, Ogilvie GK and Volk LM. Application of rapid CD3 immunophenotype analysis and argyrophilic nucleolar organizer region (AgNOR) frequency to fine needle aspirate specimens from dogs with lymphoma. Veterinary Clinical Pathology 1997; 26: 6669.
  • 4
    Renwick MG, Argyle DJ, Long S, Nixon C, Gault EA and Nasir L. Telomerase activity and telomerase reverse transcriptase catalytic subunit expression in canine lymphoma: correlation with Ki67 immunoreactivity. Veterinary and Comparative Oncology 2006; 4: 141150.
  • 5
    Zanatta R, Abate O, D'Angelo A, Miniscalco B and Mannelli A. Diagnostic and prognostic value of serum lactate dehydrogenase (LDH) and LDH isoenzymes in canine lymphoma. Veterinary Research Communications 2003; 27(Suppl. 1): 449452.
  • 6
    Roman J, Alvarez MA and Torres A. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation. Haematologica 2000; 85: 10721082.
  • 7
    Rambaldi A, Lazzari M, Manzoni C, Carlotti E, Arcaini L, Baccarani M, Barbui T, Bernasconi MC, Dastoli G, Fuga G, Gamba E, Gargantini L, Gattei V, Laurea F, Lazzarino F, Mandelli F, Morra E, Pulsoni A, Ribersani M, Rossi-Ferrini PL, Rupolo M, Tura S, Zagonel V, Zaga F, Zinzani P, Reato G and Foa R. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 2002; 99: 856862.
  • 8
    Hannigan BM, Barnett YA, Armstrong DB, McKelvey-Martin VJ and McKenna PG. Thymidine kinases: the enzymes and their clinical usefulness. Cancer Biotherapy 1993; 8: 189197.
  • 9
    von Euler H, Einarsson R, Olsson U, Lagerstedt AS and Eriksson S. Serum thymidine kinase activity in dogs with malignant lymphoma: a potent marker for prognosis and monitoring the disease. Journal of Veterinary Internal Medicine 2004; 18: 696702.
  • 10
    Von Euler HP, Rivera P, Aronsson AC, Bengtsson C, Hansson LO and Eriksson SK. Monitoring therapy in canine malignant lymphoma and leukemia with serum thymidine kinase 1 activity – evaluation of a new, fully automated non-radiometric assay. International Journal of Oncology 2009; 34: 505510.
  • 11
    Hahn KA, Freeman KP, Barnhill MA and Stephen EL. Serum alpha 1-acid glycoprotein concentrations before and after relapse in dogs with lymphoma treated with doxorubicin. Journal of the American Veterinary Medical Association 1999; 214: 10231025.
  • 12
    Sherley JL and Kelly TJ. Regulation of human thymidine kinase during the cell cycle. Journal of Biological Chemistry 1988; 263: 83508358.
  • 13
    O'Neill KL, Buckwalter MR and Murray BK. Thymidine kinase: diagnostic and prognostic potential. Expert Review of Molecular Diagnostics 2001; 1: 428433.
  • 14
    Ellims PH, Eng Gan T, Medley G and Van Der Weyden MB. Prognostic relevance of thymidine kinase isozymes in adult non-Hodgkin's lymphoma. Blood 1981; 58: 926930.
  • 15
    Ellims PH, Van der Weyden MB and Medley G. Thymidine kinase isoenzymes in human malignant lymphoma. Cancer Research 1981; 41: 691695.
  • 16
    Ellims PH, Gan TE and Van der Weyden MB. Thymidine kinase isoenzymes in chronic lymphocytic leukaemia. British Journal of Haematology 1981; 49: 479481.
  • 17
    Sadamori N, Ichiba M, Mine M, Hakariya S, Hayashibara T, Itoyama T, Nakamura H, Tomonaga H and Hayashi K. Clinical significance of serum thymidine kinase in adult T-cell leukaemia and acute myeloid leukaemia. British Journal of Haematology 1995; 90: 100105.
  • 18
    Musto P, Bodenizza C, Falcone A, D'Arena G, Scalzulli P, Perla G, Modoni S, Parlatore L, Valvano MR and Carotenuto M. Prognostic relevance of serum thymidine kinase in primary myelodysplastic syndromes: relationship to development of acute myeloid leukaemia. British Journal of Haematology 1995; 90: 125130.
  • 19
    Alvarez FJ, Kisseberth WC, Gallant SL and Couto CG. Dexamethasone, melphalan, actinomycin D, cytosine arabinoside (DMAC) protocol for dogs with relapsed lymphoma. Journal of Veterinary Internal Medicine 2006; 20: 117883.
  • 20
    Dervisis NG, Dominguez PA, Sarbu L, Newman RG, Cadile CD, Swanson CN and Kitchell B. Efficacy of temozolomide or dacarbazine in combination with an anthracycline for rescue chemotherapy in dogs with lymphoma. Journal of the American Veterinary Medical Association 2007; 231: 563569.
  • 21
    Garrett LD, Thamm DH, Chun R, Dudley R and Vail DM. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. Journal of Veterinary Internal Medicine 2002; 16: 704709.
  • 22
    Nakamura N, Momoi Y, Watari T, Yoshino T, Tsujimoto H and Hasegawa A. Plasma thymidine kinase activity in dogs with lymphoma and leukemia. Journal of Veterinary Medical Science 1997; 59: 957960.
  • 23
    Chang CM, Schroeder JC, Huang WY, Dunphy CH, Baric RS, Olshan AF, Dorsey K, Dent G, Cerhan J, Lynch C, Rothman N, Cantor N and Blair A. Non-Hodgkin lymphoma (NHL) subtypes defined by common translocations: utility of fluorescence in situ hybridization (FISH) in a case-control study. Leuk Res 2010; 34: 190195.
  • 24
    Fournel-Fleury C, Ponce F, Felman P, Blavier A, Bonnefont C, Chabanne L, Ghernati I and Magnol JP. Canine T-cell lymphomas: a morphological, immunological, and clinical study of 46 new cases. Veterinary Pathology 2002; 39: 92109.
  • 25
    Ponce F, Magnol JP, Ledieu D, Marchal T, Turinelli V, Chalvet-Monfray K and Fournel-Fleury C. Prognostic significance of morphological subtypes in canine malignant lymphomas during chemotherapy. Veterinary Journal 2004; 167: 158166.
  • 26
    Ponce F, Magnol JP, Marchal T, Chabanne L, Ledieu D, Bonnefont C, Felman P and Fournel-Fleury C. High-grade canine T-cell lymphoma/leukemia with plasmacytoid morphology: a clinical pathological study of nine cases. Journal of Veterinary Diagnostic Investigation 2003; 15: 330337.
  • 27
    Ponce F, Marchal T, Magnol JP, Turinelli V, Ledieu D, Bonnefont C, Pastor M, Delignette ML and Fournel-Fleury C. A morphological study of 608 cases of canine malignant lymphoma in France with a focus on comparative similarities between canine and human lymphoma morphology. Veterinary Pathology 2010; 47: 414433.
  • 28
    Valli VE, Vernau W, de Lorimier LP, Graham PS and Moore PF. Canine indolent nodular lymphoma. Veterinary Pathology 2006; 43: 29.
  • 29
    Gion M and Daidone MG. Circulating biomarkers from tumour bulk to tumour machinery: promises and pitfalls. European Journal of Cancer 2004; 40: 26132622.
  • 30
    Michael A, Relph K and Pandha H. Emergence of potential biomarkers of response to anti-angiogenic anti-tumour agents. International Journal of Cancer 2010; 127: 12511258.
  • 31
    Roobol MJ, Haese A and Bjartell A. Tumour markers in prostate cancer III: biomarkers in urine. Acta Oncologica 2011; 50(Suppl. 1): 8589.
  • 32
    Bjartell A, Montironi R, Berney DM and Egevad L. Tumour markers in prostate cancer II: diagnostic and prognostic cellular biomarkers. Acta Oncol 2011; 50(Suppl. 1): 7684.
  • 33
    Bon GG, Kenemans P, Verstraeten R, van Kamp GJ and Hilgers J. Serum tumor marker immunoassays in gynecologic oncology: establishment of reference values. American Journal of Obstetrics & Gynecology 1996; 174(1 Pt 1): 107114.
  • 34
    Eyestone WH. Malignant lymphoma in the dog. Acta Unio Internationalis Contra Cancrum 1952; 8: 536538.
  • 35
    Ma S, Zhang Y, Huang J, Han X, Holford T, Lan Q, Rothman N, Boyle P and Zheng T. Identification of non-Hodgkin's lymphoma prognosis signatures using the CTGDR method. Bioinformatics 2009; 26: 1521.
  • 36
    Gavazza A, Lubas G, Valori E and Gugliucci B. Retrospective survey of malignant lymphoma cases in the dog: clinical, therapeutical and prognostic features. Veterinary Research Communications 2008; 32(Suppl. 1): S291S293.
  • 37
    Yamazaki J, Baba K, Goto-Koshino Y, Setoguchi-Mukai A, Fujino Y, Ohno K and Tsujimoto H. Quantitative assessment of minimal residual disease (MRD) in canine lymphoma by using real-time polymerase chain reaction. Veterinary Immunology and Immunopathology 2008; 126: 321331.